Phytopharm near to deal on hoodia products?

Related tags License

UK firm Phytopharm, which has isolated the appetite-suppressing
ingredients in the desert plant hoodia, says it is in advanced
talks to license its compound to a food industry partner.

The company has invested more than $18 million in research on its P57 molecule, since first identifying active fractions of the hoodia plant, an extremely rare cactus native to the Kalahari desert, in 1997.

It had initially struck a deal with drug company Pfizer to bring the product to market but after this fell through last year, it set its sights on the booming meal replacement market.

Reporting growing losses last week, chief executive Richard Dixey said advanced discussions with a licensing partner were ongoing.

Some analysts believe that a deal with a major food company could be worth more than $50 million a year in royalties, with pressure on the food industry to stem the rise in obesity driving demand for new, natural weight loss ingredients.

Earlier this year, it raised approximately £6.5 million (€9.7m) through a share placement to increase supplies of the raw material in anticipation of new licensing agreements.

Related news

Related products

show more

Custom Biotic Solutions for Digestive Health

Custom Biotic Solutions for Digestive Health

Content provided by ADM: Innovation that Feeds the Future | 10-Oct-2023 | White Paper

A growing body of evidence shows gut health can affect digestive health, well-being, and many health areas in between.

Activate the

Activate the "master metabolic regulator!”

Content provided by Gencor | 18-May-2023 | Product Brochure

ActivAMP® is extracted from an adaptogenic herb, that contains a family of compounds that upregulate alarmins - including sestrins – which activate an...

Related suppliers

Follow us


View more